(16 April 2008, Cambridge, UK) Linguamatics Ltd, a leader in natural language processing (NLP) for the life science market, today announced that Pfizer has extended its strategic collaboration with Linguamatics to use the I2E knowledge discovery platform for text mining across their R&D organization. Pfizer researchers and other decision-makers will use I2E to discover and extract key facts and relationships from internal and external literature sources to support decision-making. Financial details of the agreement were not disclosed.
"High performance text mining is strategically important for any global pharma company, and especially a market leader like Pfizer," said Giles Day, Senior Director of R&D Informatics, Pfizer. "Our expanded collaboration with Linguamatics underlines our commitment to exploit the value of intelligence from text within our R&D operations. For example, the use of I2E supports our DKTP (Deep Knowledge of Targets and Pathways) strategy to find novel relationships between diseases and targets for rapid identification of therapeutically relevant targets."
"Linguamatics I2E has been used to date for focused knowledge discovery from large document collections in a variety of R&D applications at Pfizer," added David de Graaf, Director Systems Biology, Pfizer. "We are now also applying its agile NLP-based querying to inform research decisions within the new Biotherapeutics and Bioinnovation Center."
"We are delighted that Pfizer has chosen to expand our collaboration," commented Roger Hale, COO and Co-founder of Linguamatics. "Working with world-leaders like Pfizer supports our strategy of driving value from state-of-the-art text mining throughout large enterprises."
ABOUT PFIZER
Pfizer is the world's largest research-based biomedical and pharmaceutical company. Pfizer's corporate headquarters are located in New York, with major research and development locations in the United States and England. Recent innovations include Sutent® -- a novel cancer medicine that both cuts off the blood supply that feeds tumors and destroys cellular reproduction, and Chantix™ -- a new prescription medicine and accompanying support plan designed specifically to help smokers quit. In 2006, Pfizer earned $48.4 billion in revenues and invested $7.6 billion in research and development.
ABOUT LINGUAMATICS LTD
Linguamatics helps organizations to maximize the value derived from information resources through effective deployment of innovative natural language processing (NLP) based technology. The versatile interactive information extraction system, I2E, helps organizations to do much more than simply cope with vast quantities of information. Its unique combination of search and text mining helps organizations to turn this information into a competitive advantage. From life sciences and healthcare to business intelligence, from media analysis to security, users mine large collections of documents, extracting relevant facts, relationships and quantitative data from content such as scientific papers, news feeds, patents, or internal reports. Linguamatics has a rapidly growing user community with I2E deployed at most top-10 pharma companies. The company was founded in 2001, and is based in Cambridge, UK.
ABOUT I2E
Linguamatics' flagship I2E technology combines four key capabilities to enable users to rapidly extract relevant facts and relationships from large document collections:
I2E features a client-server architecture built using industry-standard Java and C for use by single users, project teams, or in enterprise-wide deployments. Organizations have full control over source content to be mined, definition of queries and results output.
For further information on Linguamatics products and solutions, visit www.linguamatics.com.
The Linguamatics logo is a trademark of Linguamatics Ltd. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.
For further information please contact:
Judith Bandy
Linguamatics Ltd.
Tel: +44 (0)7912 944385
Email: judith.bandy@linguamatics.com
www.linguamatics.com